A Phase 1 interventional study of Tirzepatide and Acetaminophen in Overweight, Obesity and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-08.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 79th largest by enrollment, is one of 3 that started in 2020, is one of 12 in phase 1, and was the 4th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 107th largest by enrollment of the 117 interventional ones that give a count, is one of 3 that started in 2020, is one of 40 in phase 1, and was the 5th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.
The study will last about 13 weeks for each participant, including screening.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 36 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria:
Key Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 5mg tirzepatide on Day 1 and Day 8; 10 mg tirzepatide on Day 15, 22 and 29; 15 mg tirzepatide on Day 36 administered subcutaneously (SC) and 160 mg acetaminophen administered orally on Day -1, Day 2 and Day 37.
Drug: Tirzepatide · Drug: Acetaminophen
Tirzepatide administered SC.
Also known as: LY3298176
Acetaminophen administered orally.
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen
Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen
Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen
Maximum Observed Drug Concentration (cmax) of Acetaminophen
Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
Hemoglobin A1c (HbA1c) Data by Diabetic Status
Levels of Hemoglobin A1c (HbA1c) were assessed at predose on Day 29, and at follow-up (Day 64).
Time frame: Predose on Day 29 and follow-up (Day 64)
PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For Non-diabetic
Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen at Steady State For Non-diabetic
Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
PK: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For T2DM
Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen at Steady State For T2DM
Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
PK: Cmax of Acetaminophen at Steady State Non-diabetic
PK: Cmax of Acetaminophen at Steady State Non-diabetic
Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
PK: Cmax of Acetaminophen at Steady State For T2DM
PK: Cmax of Acetaminophen at Steady State T2DM
Time frame: Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, 24 and 36 hours post-dose on Day 1, Day 2 and Day 37 , Day 2 and Day 37
| Milestone | Non-Diabetic | Type 2 Diabetes Mellitus (T2DM) |
|---|---|---|
| Started | 18 | 18 |
| Received at least one dose of study drug | 18 | 18 |
| Completed | 15 | 15 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 3 | 3 |
Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen
| nanograms*hours per milliliter (ng*h/mL) | Reference:160 mg Acetaminophen (Day -1) | Test: 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) | Test: 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37) |
|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen | 49384 (43635 to 55890) | 43523 (38456 to 49257) | 57049 (50171 to 64869) |
Maximum Observed Drug Concentration (cmax) of Acetaminophen
| nanograms per milliliter (ng/mL) | Reference:160 mg Acetaminophen (Day -1) | Test: 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) | Test: 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37 |
|---|---|---|---|
| PK: Maximum Observed Drug Concentration (Cmax) of Acetaminophen | 11925 (10566 to 13460) | 5314 (4708 to 5998) | 8099 (7111 to 9225) |
Levels of Hemoglobin A1c (HbA1c) were assessed at predose on Day 29, and at follow-up (Day 64).
| Percentage of HbA1c | Non-Diabetic | T2DM |
|---|---|---|
| Day 29 ± 1 | 5.37 ± 0.45 | 7.27 ± 0.79 |
| Day 64 ± 1 (Follow-Up) | 5.29 ± 0.45 | 6.87 ± 0.75 |
Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen at Steady State For Non-diabetic
| nanograms*hours per milliliter (ng*h/mL) | Reference (Non-diabetic):160 mg Acetaminophen (Day -1) | Test (Non-diabetic): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) | Test (Non-diabetic): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37) |
|---|---|---|---|
| PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For Non-diabetic | 44350 (37276 to 52766) | 39389 (33107 to 46864) | 54735 (45695 to 65563) |
Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration \[ AUC(0-tlast)\] of Acetaminophen at Steady State For T2DM
| nanograms*hours per milliliter (ng*h/mL) | Reference (T2DM):160 mg Acetaminophen (Day -1) | Test (T2DM): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) | Test (T2DM): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37) |
|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of Acetaminophen at Steady State For T2DM | 54989 (46219 to 65424) | 48090 (40420 to 57215) | 59440 (49623 to 71199) |
PK: Cmax of Acetaminophen at Steady State Non-diabetic
| nanograms per milliliter (ng/mL) | Reference (Non-diabetic):160 mg Acetaminophen (Day -1) | Test (Non-diabetic): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) | Test (Non-diabetic): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37) |
|---|---|---|---|
| PK: Cmax of Acetaminophen at Steady State Non-diabetic | 10255 (8680 to 12115) | 4646 (3932 to 5489) | 8245 (6891 to 9866) |
PK: Cmax of Acetaminophen at Steady State T2DM
| nanograms per milliliter (ng/mL) | Reference (T2DM):160 mg Acetaminophen (Day -1) | Test (T2DM): 5 mg Tirzepatide + 160 mg Acetaminophen (Day 2) | Test (T2DM): 15 mg Tirzepatide + 160 mg Acetaminophen (Day 37) |
|---|---|---|---|
| PK: Cmax of Acetaminophen at Steady State For T2DM | 13868 (11738 to 16385) | 6078 (5144 to 7181) | 7954 (6648 to 9517) |
Collected over Baseline Up To 45 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Non-diabetic | 0/18 (0%) | 0/18 (0%) | 16/18 (88.9%) |
| T2DM | 0/18 (0%) | 0/18 (0%) | 16/18 (88.9%) |
| Event | Non-diabetic | T2DM |
|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 16/18 | 4/18 |
| NauseaGastrointestinal disorders | 7/18 | 14/18 |
| Abdominal distensionGastrointestinal disorders | 6/18 | 8/18 |
| VomitingGastrointestinal disorders | 3/18 | 7/18 |
| ConstipationGastrointestinal disorders | 4/18 | 2/18 |
| DyspepsiaGastrointestinal disorders | 1/18 | 4/18 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 4/18 | 0/18 |
| Back painMusculoskeletal and connective tissue disorders | 1/18 | 4/18 |
| FatigueGeneral disorders | 1/18 | 3/18 |
| HeadacheNervous system disorders | 3/18 | 2/18 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Non-Diabetic | T2DM | Total |
|---|---|---|---|
| Mean | 43.9 ± 10.8 | 56.2 ± 5.5 | 50.1 ± 10.5 |
| Sex: Female, Male(Participants) | Non-Diabetic | T2DM | Total |
|---|---|---|---|
| Female | 10 | 13 | 23 |
| Male | 8 | 5 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Non-Diabetic | T2DM | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 18 | 36 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Non-Diabetic | T2DM | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 14 | 16 | 30 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Non-Diabetic | T2DM | Total |
|---|---|---|---|
| United States | 18 | 18 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Jan 2021, 3 months.
Results were first posted in Jan 2024, 3 years after primary completion.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide